Skye Bioscience Announces Participation in February Conferences
Rhea-AI Summary
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biopharmaceutical company focused on obesity and metabolic health disorders, has announced its participation in two upcoming investor conferences in February 2025.
The company will participate in the BIO CEO & Investor Conference in New York on February 10, where they will join a panel discussion on 'Obesity: Next Medicines with Impact' at 11:00 AM ET. Additionally, Skye will present a corporate overview at the virtual Oppenheimer 35th Healthcare Life Sciences Conference on February 12 at 12:00 PM ET. A webcast of the presentation will be available on Skye's website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SKYE gained 0.17%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following investor conferences:
BIO CEO & Investor Conference
New York
Panel: Obesity: Next Medicines with Impact
Monday, February 10, 2025, 11:00 AM - 11:50 AM ET
Oppenheimer 35th Healthcare Life Sciences Conference
Virtual
Corporate overview
Wednesday, February 12th, 2025, at 12:00 PM - 12:30 PM ET
A live and archived webcast will be accessible on Skye’s website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
When is Skye Bioscience (SKYE) presenting at the BIO CEO & Investor Conference in February 2025?
What is the schedule for Skye Bioscience's (SKYE) presentation at the Oppenheimer Healthcare Conference?
How can investors access Skye Bioscience's (SKYE) Oppenheimer conference presentation?
What therapeutic areas is Skye Bioscience (SKYE) focusing on as of February 2025?
